MediPoint: 切片設備 - 歐盟市場分析及未來預測
MediPoint: Biopsy Devices - EU Analysis and Market Forecasts
|出版日期||內容資訊||英文 131 Pages
|MediPoint: 切片設備 - 歐盟市場分析及未來預測 MediPoint: Biopsy Devices - EU Analysis and Market Forecasts|
|出版日期: 2014年02月28日||內容資訊: 英文 131 Pages||
Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.
While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.